Replimune Group earnings date
Want to see REPL full AI Analyst Report?
Replimune Group (REPL) Q2 2027 Earnings Report
REPL Q2 2027 EPS Results
- Actual EPS
- -$0.54
- Consensus EPS
- -$0.78
- Beat/Miss
- Beat by +$0.24
- One Year Ago EPS
- -$0.90
REPL Q2 2027 Revenue Results
- Actual Revenue
- $0
- Expected Revenue
- $0
- Beat/Miss
- Met expectations
- YoY Revenue Growth
- ―
Earnings Announcement Details
- Quarter
- Q2 2027
- Date
- 10/29/2026
- Time
- TBA
- Conference Call
- Thursday, October 29, 2026
Replimune Group's next earnings date is estimated for August 12, 2027, based on past reporting schedules.
Q2 2027 Earnings Call Audio
Q2 2027 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2027 Earnings Call Summary
The call was strongly optimistic about TUDRIQEV's early commercial launch, with rapid account engagement, formulary additions, prescriptions, payer coverage, next-day delivery, and adoption across both academic and regional centers. The company also reported a stronger cash position and improved sequential net loss. Offsetting concerns were the absence of current-quarter product revenue, continued operating losses, higher SG&A tied to launch activities, lack of revenue guidance, and limited visibility into patient volumes and real-world treatment economics. Overall, the positive launch commentary and early adoption metrics significantly outweighed the stated challenges.
Management will not be providing revenue guidance at this time; the list price of TUDRIQEV is $450,000 per course of therapy before customary rebates and discounts, patients may receive 8 or more cycles, and revenue from a patient starting therapy may be recognized over more than 1 quarter. Replimune expects its cash position to fund operations for greater than 12 months, anticipates having a permanent J-code in place by April 2027, and said it could sort of double the number of accounts already initiating patients by the end of the year. The company’s priority in the first 6 months is the top 200 accounts, representing about 30% of melanoma patients treated nationally each year, followed by the next wave of 250 accounts representing another 20% of the melanoma population; it will continue to assess accelerating into these accounts and the community.
- Successful Early Launch of TUDRIQEVTUDRIQEV launched in early October 2026 as Replimune's first commercial product from its RPx platform. In the first 3 weeks, leading melanoma institutions had already ordered the product, and many others had identified patients for treatment.
- Strong Physician and Institutional InterestAcademic and community oncologists, as well as interventional radiologists, expressed strong interest in adopting TUDRIQEV. More than 70% of the initial 200 target accounts had been proactively engaged, and more than 50 meetings with melanoma treaters and sites had been held.
- Rapid Formulary and Prescription ProgressApproximately 20 accounts had placed TUDRIQEV on formulary, and more than 15 institutions had written at least one prescription within fewer than 20 business days of launch. As of the morning of the call, closer to 20 accounts had ordered, established workflows, and begun treating patients.
- Adoption by Leading Melanoma CentersHigh-volume institutions including Moffitt and Memorial Sloan Kettering moved quickly to add TUDRIQEV to formulary and treat patients. Most of the initial treating institutions were academic and hospital-based centers, in line with the company's expectations.
- Unexpectedly Fast Regional Center AdoptionSeveral regional centers adopted TUDRIQEV quickly and successfully, including for both superficial and deep injections. The company also received proactive outreach from community practices outside its initial target list of 200 accounts, and some accounts without prior TUDRIQEV experience had already treated patients.
- Broad Label and Flexible Treatment UseThe broad TUDRIQEV label allows physicians to treat patients progressing on PD-1-based therapy without requiring prior BRAF-targeted therapy. The label covers patients from the adjuvant, frontline, and second-line settings, and physicians are expected to use the therapy both earlier and later in the treatment sequence depending on patient need.
- Fast Delivery and Just-in-Time TreatmentTUDRIQEV can be delivered the next day for outpatient administration. The company cited examples of orders placed on Friday for treatment on Tuesday and orders placed on Monday for treatment on Tuesday.
- Superficial and Image-Guided Injection AdoptionEarly adoption included both superficial and image-guided injections, including deep visceral lesions. The company said interventional radiologists were receptive and that some accounts were scheduling patients for all 8 cycles with interventional radiology when appropriate.
- Broad Payer CoverageTUDRIQEV was rapidly listed in the NCCN guidelines as a Category 2A recommendation. Many commercial payers had published on-label coverage policies, including retreatment when clinically appropriate, and those policies represented a majority of commercially covered lives. Medicare coverage had also been established.
- No Reported Volume Restrictions in Published PoliciesThe company said published payer policies did not impose volume restrictions and supported the labeled 8 cycles and retreatment as necessary. Some policies allowed up to 24 doses.
- Patient Support Program OperationalReplimuneConnect Plus was live and providing support services intended to facilitate patient access to TUDRIQEV.
- Commercial Organization Nearly Fully StaffedThe company said it had rebuilt and rightsized its commercial team, with all 23 account management positions in place and the operational excellence team almost fully staffed. The customer-facing team was actively engaging target accounts.
- Supply ReadinessReplimune reported more than one year of TUDRIQEV inventory on hand, produced at its in-house manufacturing facility, and said it was ready to meet demand with next-day delivery.
- Cash Position StrengthenedCash and cash equivalents were $307.8 million at September 30, 2026, including net proceeds of $141 million from the August offering, compared with $195.3 million at June 30. This represents an increase of approximately 57.6%. Management expects the current cash position to fund operations for greater than 12 months.
- Quarterly Net Loss ImprovedNet loss was $57.1 million in the fiscal second quarter, compared with $69.8 million in the fiscal first quarter, an improvement of approximately 18.2%.
- R&D Expenses DeclinedResearch and development expenses were $34.4 million, down from $49.3 million in the fiscal first quarter, a decrease of approximately 30.2%.
- Pipeline Studies Enrolling WellThe REVEAL study of RP2 in uveal melanoma and the confirmatory melanoma study IGNYTE-3, which had opened additional sites in Europe, were both enrolling well.
- Potential Expansion Beyond Initial 200 AccountsThe company plans to focus on its initial 200 accounts during the first 6 months, representing approximately 30% of melanoma patients treated annually in the U.S., and is considering accelerating into another 250 accounts representing an additional 20% of the melanoma population.
- Commercial Pricing EstablishedThe list price of TUDRIQEV was set at $450,000 per course of therapy before customary rebates and discounts. The actual cost per patient will vary based on tumor burden and the number of treatment cycles, with patients potentially receiving 8 or more cycles.
REPL Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Aug 12, 2027 | 2028 (Q1) | ―- | -0.72 | ― | ― |
| Oct 29, 2026 | 2027 (Q2) | -0.78-0.54 | -0.9 | 40.00% (+0.36) | |
| Aug 14, 2026 | 2027 (Q1) | -0.69-0.72 | -0.95 | 24.21% (+0.23) | |
| Jun 29, 2026 | 2026 (Q4) | -0.66-0.76 | -0.82 | 7.32% (+0.06) | |
| Feb 03, 2026 | 2026 (Q3) | -0.76-0.77 | -0.79 | 2.53% (+0.02) | |
| Nov 06, 2025 | 2026 (Q2) | -0.74-0.90 | -0.68 | -32.35% (-0.22) | |
| Aug 07, 2025 | 2026 (Q1) | -0.79-0.95 | -0.78 | -21.79% (-0.17) | |
| May 22, 2025 | 2025 (Q4) | -0.71-0.82 | -0.82 | 0.00% (+0.00) | |
| Feb 06, 2025 | 2025 (Q3) | -0.71-0.79 | -0.77 | -2.60% (-0.02) | |
| Nov 12, 2024 | 2025 (Q2) | -0.82-0.68 | -0.9 | 24.44% (+0.22) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
